Carregant...
Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease
BACKGROUND AND AIMS: Vedolizumab (VDZ) is effective for Crohn’s disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. METHODS: Phase 3 clinical trial data on VZD for CD were used to pr...
Guardat en:
| Publicat a: | Inflamm Bowel Dis |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6231370/ https://ncbi.nlm.nih.gov/pubmed/29668915 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ibd/izy031 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|